74.71 +0.01 (0.01%)
After hours: 5:19PM EDT
|Bid||73.75 x 800|
|Ask||76.00 x 2200|
|Day's Range||74.32 - 74.85|
|52 Week Range||58.81 - 75.62|
|PE Ratio (TTM)||49.87|
|Earnings Date||Jul 26, 2018|
|Forward Dividend & Yield||0.76 (1.02%)|
|1y Target Est||78.86|
Baxter CEO Jose Almeida discusses future M&A, new product launches, and gearing up for hurricane season with CNBC's Meg Tirrell.
Baxter International Inc. (BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.19 per share of common stock. The indicated annual dividend rate is $0.76 per share of common stock. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Over the last one-month, outflows of investor capital in ETFs holding BAX totaled $51 million.
Baxter's (BAX) Q2 earnings likely to be aided by promising international ventures and acquisitions; cyclophosphamide competition raises concern.
Stock Research Monitor: ATRS and BAX LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on AKER sign up now at www.wallstequities.com/registration . On Tuesday, July 03, 2018, US ...
Baxter International (BAX), will host a conference call to discuss its second quarter 2018 financial results on Thursday, July 26, 2018, at 7:30 a.m. Central Time. The Conference ID is 2998733. Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products.
Stryker (SYK) and Baxter's (BAX) strong expected growth rates and rising share price make them close contenders in the MedTech industry.
Baxter International Inc. (BAX), a leading global medical products company, today released its 2017 Corporate Responsibility Report, highlighting its efforts to create lasting social, economic and environmental value in the communities the company serves around the world. The report underscores Baxter’s progress toward its 2020 Corporate Responsibility priorities and goals, which span from reducing Baxter’s environmental footprint to addressing healthcare needs within underserved communities. “Responsible corporate citizenship goes hand in hand with our mission to save and sustain lives.
I am going to run you through how I calculated the intrinsic value of Baxter International Inc (NYSE:BAX) by taking the expected future cash flows and discounting them to today’sRead More...
After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).
Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA
Boston Scientific’s (BSX) enterprise value is $45.1 billion, and its enterprise-value-to-revenue ratio is 4.98x. The stock is trading at a forward PE multiple of 21.86x, which is expected to have a five-year growth multiple of 2.13x. Its price-to-sales ratio is 5.23x, and its price-to-book ratio is 6.72x. Its enterprise-value-to-EBITDA ratio is 18.5x.
Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.
Baxter International (BAX) has been regularly carrying out stock repurchases, a positive sign for investors. Baxter International generated $447 million from operating activities in the first quarter of 2018 compared to $206 million in Q1 2017. Baxter’s days payable outstanding increased from 48.6 days in Q1 2017 to 57.8 days in Q1 2018.
Baxter International (BAX) generated net sales of $2.7 billion in the first quarter of 2018 compared to $2.5 billion in Q1 2017. Baxter’s gross margins were affected by a negative impact from foreign exchange rates and the impact of lost sales due to Hurricane Maria and incremental supply chain costs in the first quarter. The company’s gross profit increased marginally from $1 billion in Q1 2017 to $1.1 billion in Q1 2018.
Sales from Baxter International’s (BAX) Acute Therapies rose 22%, from $106 million in Q1 2017 to $129 million in Q1 2018 on the back of higher demand for Baxter’s CRRT (continuous renal replacement therapies) systems. In July 2017, Baxter International acquired Claris Lifesciences’ subsidiary Claris Injectables for a cash consideration of $629 million. Through this acquisition, Baxter gained capabilities in the production of essential generic injectable medicines such as anesthesia and analgesics, renal, anti-infectives, and critical care in bags, vials, and ampoules.
Baxter generates a major part of its revenues from the Americas segment, which contributed $1.44 billion to the company’s total revenues in the first quarter, from $1.37 billion in Q1 2017. The company generated $724 million of revenue from its EMEA segment in the first quarter of 2018 compared to $631 million in the first quarter of 2017.
Baxter International’s (BAX) global business units include the following: Renal Care: peritoneal dialysis and hemodialysis therapies Medication Delivery: intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices Pharmaceuticals: premixed and oncology drug platforms, inhaled anesthesia, critical care products, and pharmacy compounding services Nutrition: parenteral nutrition therapies Advanced Surgery: biological products, medical devices used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention Acute Therapies and Other: continuous ...
Baxter International (BAX) provides a broad portfolio of essential healthcare products. Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating. Six have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.3 with a target price of $78.33, implying an upside potential of 4.1% over the stock’s closing price of $75.28 on June 5.